PipelineReview.com22h
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
HAYWARD, CA, USA I October 02, 2024 I Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing ...
PipelineReview.com22h
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
TEL AVIV, Israel and MADRID, Spain I October 03, 2024 I Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and ...
PipelineReview.com22h
Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers
BASEL, Switzerland I October 02, 2024 I Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...
PipelineReview.com22h
ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Under the terms of the agreement, ABL Bio will conduct a phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA. In this combination study, MSD will ...
PipelineReview.com22h
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions ...
PipelineReview.com22h
Recordati announces agreement to acquire the global rights to Enjaymo®, strengthening its rare diseases franchise
MILAN, Italy I October 04, 2024 I Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which ...
PipelineReview.com20h
Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders
— Series B led by Goldman Sachs Alternatives with participation from Fidelity Management & Research Company, Deep Track Capital, and existing investors — — Funding will advance second-generation ...